Filing Flows › Health Care › uniQure N.V. (QURE)
uniQure N.V. (QURE) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · uniQure N.V. (QURE) Q3 2026 earnings results →
Q3 2026 Revenue up 40% year over year to $5.2M
uniQure N.V. made $5.2M in Q3 2026 (+40% Y/Y). Operating margin n/m, net loss $61.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $5.2M in Q3 2026, up 40% year over year and down 11% from the previous quarter.
Operating costs exceeded revenue by $53.0M, an operating margin of -1019.6%. Total costs grew 6% against revenue growth of 40%. The quarter ended with a net loss of $61.2M, narrower than the previous quarter's $81.1M loss.
Operating cash flow was −$47.8M. Non-cash charges added back $5.5M of depreciation and amortization and $5.4M of share-based compensation. Working capital and other items added $2.5M. Capital expenditures of $11K exceeded it, leaving free cash flow of −$47.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $5.2M | +40% | n/m | −$61.2M | −$47.8M |
| Q2 2026 | 10-Q | Jul 29, 2026 | $5.8M | +11% | -893.7% | −$81.1M | −$28.6M |
| Q1 2026 | 10-Q | May 5, 2026 | $3.6M | +127% | n/m | −$53.5M | −$38.2M |
| Q4 2025 | 10-K | Mar 2, 2026 | $5.6M | +7% | -918.1% | −$37.1M | −$77.6M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $3.7M | +62% | n/m | −$80.5M | −$16.4M |
| Q2 2025 | 10-Q | Jul 29, 2025 | $5.3M | -53% | -833.6% | −$37.7M | −$39.9M |
| Q1 2025 | 10-Q | May 9, 2025 | $1.6M | -82% | n/m | −$43.6M | −$44.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About uniQure N.V.
We are a leader in the field of gene therapy, seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. We are advancing a focused pipeline of innovative gene therapies, including our clinical candidates for the treatment of Huntington’s disease, refractory mesial temporal lobe epilepsy (“MTLE”), Fabry disease, and amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 (“SOD1-ALS”). In September 2025, we announced p ositive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington’s disease. We analyzed clinical outcomes for 29 patients treated with AMT-130 (n=17 high-dose; n=12 low-dose) of which 12 patients per dose group had attained 36 months of follow-up and were evaluated at that time point.
In its own words, from its 10-K, filed Mar 2, 2026.
uniQure N.V. against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +40% against the peers' median +10%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| QURE uniQure N.V. | Q3 2026 | $5.2M | +40% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: uniQure N.V. 10-Q on SEC EDGAR · CIK 1590560 · Pharmaceutical Preparations
Guidance and outlook
More on QURE
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results